TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Mach7 Technologies ( (AU:M7T) ) is now available.
Mach7 Technologies has announced its preliminary unaudited financial results for FY25, projecting revenue of approximately A$33M-$34M, aligning with its guidance for 15-25% growth. The company also reported strong recurring revenue growth of 20% and a slightly lower than expected Contracted Annual Recurring Revenue (CARR) of A$30M-$31M. Despite this, Mach7 remains financially robust, with no debt and an anticipated positive cash flow for FY25. The company has also engaged in a share buyback, acquiring 6.3 million shares, and expects a closing cash balance of A$21M-$23M by the end of June 2025.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.95 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
More about Mach7 Technologies
Mach7 Technologies (ASX:M7T) is a leading provider of medical imaging software, offering advanced data management and diagnostic viewing solutions to healthcare organizations worldwide. Their flagship product, the Mach7 Enterprise Imaging Solution, includes a Vendor Neutral Archive, the eUnity Enterprise Diagnostic Viewer, and diagnostic workflow applications, providing flexibility and scalability for diverse healthcare networks.
Average Trading Volume: 247,257
Technical Sentiment Signal: Sell
Current Market Cap: A$82.24M
For detailed information about M7T stock, go to TipRanks’ Stock Analysis page.